European urology oncology最新文献

{"title":"Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials.","authors":"Satı Coşkun Yazgan, Emre Yekedüz, Mutlay Sayan, Praful Ravi, Hatice Bölek, Rana R McKay, Serap Akyürek, Liselotte M S Boevé, Alberto Bossi, Nicholas D James, Karim Fizazi, Silke Gillessen, Toni K Choueiri, Yüksel Ürün","doi":"10.1016/j.euo.2025.05.003","DOIUrl":"https://doi.org/10.1016/j.euo.2025.05.003","url":null,"abstract":"<p><strong>Background and objective: </strong>Despite advancements in systemic therapy for metastatic castration-sensitive prostate cancer (mCSPC), the survival benefits of radiotherapy (RT) remain uncertain. This meta-analysis evaluates whether addition of RT to the standard of care (SOC) improves radiographic progression-free (rPFS) and overall (OS) survival, with a focus on systemic therapy intensification.</p><p><strong>Methods: </strong>A targeted review of three phase 3 trials (HORRAD, STAMPEDE, and PEACE-1) was conducted to assess the role of prostate RT in mCSPC. Two reviewers evaluated study quality, and a meta-analysis using a random-effect model (Review Manager v5.3) analyzed rPFS and OS as the primary outcomes (hazard ratio [HR] with 95% confidence interval [CI]). Subgroup analyses focused on low-volume disease as per the CHAARTED criteria, with heterogeneity assessed via I² and significance set at p < 0.05.</p><p><strong>Key findings and limitations: </strong>This meta-analysis of 3665 patients from HORRAD, STAMPEDE, and PEACE-1 found that addition of RT to SOC did not improve rPFS or OS in the overall mCSPC population. However, in low-volume disease, RT with SOC and abiraterone acetate (AA) improved rPFS significantly (HR = 0.65, 95% CI: 0.45-0.93; p = 0.02) without an OS benefit. Limitations include pooled data, patient heterogeneity, and variations in treatments and follow-up.</p><p><strong>Conclusions and clinical implications: </strong>Prostate RT does not improve rPFS or OS in the overall mCSPC population, but offers a significant rPFS benefit in low-volume disease when combined with SOC and AA. Although no OS improvement was observed, the synergy between AA and RT underscores the value of RT for carefully selected patients. Further prospective studies are needed to refine treatment strategies and improve outcomes.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Trends in the Incidence, Mortality, and Risk-attributable Deaths for Prostate, Bladder, and Kidney Cancers: A Systematic Analysis from the Global Burden of Disease Study 2021.","authors":"David Ka-Wai Leung, Chris Ho-Ming Wong, Ivan Ching-Ho Ko, Brian Wai-Hei Siu, Alex Qin-Yang Liu, Henry Yue-Hong Meng, Steffi Kar-Kei Yuen, Sikun Chen, Qingqing Hu, Chi-Fai Ng, Jeremy Y C Teoh","doi":"10.1016/j.euo.2025.05.007","DOIUrl":"https://doi.org/10.1016/j.euo.2025.05.007","url":null,"abstract":"<p><strong>Background and objective: </strong>Bladder cancer (BCa), kidney cancer (renal cell carcinoma [RCC]), and prostate cancer (PCa) altogether contribute remarkably to global cancer morbidity and mortality. However, comprehensive global assessments of their incidence and mortality trends are lacking. This study aimed to assess the global, regional, and national burden of the urological cancers using the most updated data from the Global Burden of Disease (GBD) 2021 study.</p><p><strong>Methods: </strong>Data on these urological cancers were extracted from the GBD 2021 database. Age-standardized incidence rates (ASIRs) and age-standardized death rates (ASDRs) were calculated by sex, region, and sociodemographic index (SDI).</p><p><strong>Key findings and limitations: </strong>In 2021, there were 2.25 million new cases and 815 546 deaths from urological cancers globally. PCa had the highest incidence and mortality burden, followed by BCa and RCC. From 2000 to 2021, ASIR increased for RCC (average annual percent change [AAPC]: 0.15%, 95% confidence interval [CI] 0.07-0.23%), while it declined for BCa (AAPC: -0.48%, 95% CI -0.54% to -0.43%) and PCa (AAPC: -0.12%, 95% CI -0.24% to -0.01%). ASDRs decreased for all three cancers, with BCa showing the largest reduction (AAPC: -1.02%, 95% CI -1.08 to -0.97%). The incidences were higher in high- to middle-SDI regions. Smoking and a high body mass index were the leading causes of risk-attributable deaths of urological cancers.</p><p><strong>Conclusions and clinical implications: </strong>The GBD 2021 study revealed that the incidences and mortality burden of these urological cancers remained significant. Public health strategies targeting early detection and modifiable risk factors are crucial to further reduce the evolving burden of these cancers.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hall of Fame","authors":"","doi":"10.1016/S2588-9311(25)00153-1","DOIUrl":"10.1016/S2588-9311(25)00153-1","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 3","pages":"Page ix"},"PeriodicalIF":8.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144167923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data.","authors":"Quynh Chi Le, Carolin Siech, Benedikt Hoeh, Fred Saad, Felix Preisser, Derya Tilki, Markus Graefen, Tobias Maurer, Maximilian C Kriegmair, Pierre I Karakiewicz, Felix K H Chun, Philipp Mandel, Mike Wenzel","doi":"10.1016/j.euo.2025.05.006","DOIUrl":"https://doi.org/10.1016/j.euo.2025.05.006","url":null,"abstract":"<p><strong>Background and objective: </strong>Recently published data comparing the impact and duration of androgen deprivation therapy (ADT) on metastasis-free survival (MFS), progression-free survival (PFS), and overall survival (OS) in patients undergoing salvage radiation therapy (sRT) after radical prostatectomy have not been compared directly; this study aims to address this knowledge gap.</p><p><strong>Methods: </strong>We performed a systematic review and network meta-analysis (NMA) on MFS, PFS, and OS using data from the RADICALS-HD, NRG/RTOG 9601, RTOG 0534, and GETUG-AFU 16 trials, as well as three trials from the ARTISTIC meta-analysis (GETUG-AFU 17, RADICALS-RT, and RAVES) on adjuvant versus salvage radiotherapy. The primary outcome was MFS; the secondary outcomes were PFS and OS. Stratification was made according to ADT duration (ADT for 24 mo vs ADT for 6 mo vs no ADT). Subgroup analyses addressed high-risk cohorts with Gleason score ≥8 and positive surgical margins (PSMs).</p><p><strong>Key findings and limitations: </strong>Data from 3710 prostate cancer patients were analyzed. Addition of ADT to sRT improved MFS and PFS significantly, regardless of the duration, but had no significant effect on OS. Hazard ratios (HRs) for ADT for 24 mo versus no ADT were 0.70 (confidence interval [CI] 0.53-0.92) for MFS, 0.51 (CI 0.43-0.61) for PFS, and 0.80 (CI 0.63-1.01) for OS; for ADT for 6 mo versus no ADT, the respective HRs were 0.79 (CI 0.65-0.97), 0.57 (CI 0.48-0.67), and 0.93 (CI 0.72-1.20). In subgroup analyses, ADT for 24 mo was ranked highest for MFS in patients with PSMs and Gleason score ≥8.</p><p><strong>Conclusions and clinical implications: </strong>The NMA supports the addition of ADT to sRT, particularly a 24-mo duration, which provides the best MFS and PFS outcomes. While OS did not improve significantly, patients with Gleason score ≥8 or PSMs also benefit from prolonged ADT.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients\" [Eur. Urol. Oncol. 7 (2024) 954-964].","authors":"Natalia Jiménez, Marta Garcia de Herreros, Òscar Reig, Mercedes Marín-Aguilera, Caterina Aversa, Laura Ferrer-Mileo, Samuel García-Esteve, Leonardo Rodríguez-Carunchio, Isabel Trias, Albert Font, Alejo Rodriguez-Vida, Miguel Ángel Climent, Sara Cros, Isabel Chirivella, Montserrat Domènech, Mariona Figols, Joan Carles, Cristina Suárez, Daniel Herrero Rivera, Enrique González-Billalabeitia, Claudia Cívico, Núria Sala-González, Vicenç Ruiz de Porras, Maria J Ribal, Aleix Prat, Begoña Mellado","doi":"10.1016/j.euo.2025.05.011","DOIUrl":"https://doi.org/10.1016/j.euo.2025.05.011","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Practices and Perspectives on Prostate Biopsy Techniques Among Urologists: A European Survey.","authors":"Alessandro Uleri, Romain Diamand, Gaelle Fiard, Francesco Sanguedolce, Jonathan Olivier, Raphaele Renard-Penna, Arthur Peyrottes, Guillaume Ploussard, Michael Baboudjian","doi":"10.1016/j.euo.2025.05.009","DOIUrl":"https://doi.org/10.1016/j.euo.2025.05.009","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency.","authors":"Ruben Raychaudhuri, Heather H Cheng, Roman Gulati, Michael T Schweizer, Aaron Lin, Todd Yezefski, Hiba M Khan, Evan Y Yu, Jessica E Hawley, Peter S Nelson, Colin C Pritchard, Bruce Montgomery","doi":"10.1016/j.euo.2025.04.026","DOIUrl":"https://doi.org/10.1016/j.euo.2025.04.026","url":null,"abstract":"<p><strong>Background and objective: </strong>Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring alterations in homologous recombination repair (HRR) genes in comparison to a historical control cohort treated with PARPi monotherapy.</p><p><strong>Methods: </strong>This single-arm, open-label, investigator-initiated phase 2 trial (NCT02985021) enrolled 18 patients with mCRPC with pathogenic alterations in HRR genes between 2018 and 2021 at a single center. Patients received four cycles of induction chemotherapy with docetaxel (60 mg/m²) and carboplatin (area under the curve 5) every 21 d, followed by maintenance rucaparib (600 mg twice daily) until progression or unacceptable toxicity. The primary outcome was radiographic progression-free survival (rPFS). Subsequent to study inception, multiple other studies reported alterations in genes of the BRCA complex (BRCA-C: BRCA1, BRCA2, PALB2) as most predictive of PARPi response; therefore, a post hoc analysis comparing patients with alterations in BRCA-C genes to a historical control cohort was performed.</p><p><strong>Key findings and limitations: </strong>After median follow-up of 40.3 mo (interquartile range 38.5-not reached [NR]), the median rPFS for all patients was 8.1 mo (95% confidence interval [CI] 6.5-31.2), similar to a historical control cohort treated with PARPi monotherapy. Among the 12 patients with BRCA-C alterations, median rPFS was 17.7 mo (95% CI 7.5-NR; p = 0.05). A key limitation is the single-arm design.</p><p><strong>Conclusions and clinical implications: </strong>Induction platinum-based chemotherapy followed by maintenance PARPi therapy did not improve outcomes for patients with mCRPC broadly selected for HRR deficiency. However, results were promising in the more stringently selected group with BRCA-C gene alterations. Further studies comparing this approach to PARPi monotherapy are warranted.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic Versus Open Radical Prostatectomy, Differences in Prostate Cancer-specific Survival-12 Years of Follow-up in the LAParoscopic Prostatectomy Robot Open Trial.","authors":"Anna Lantz, Ying Li, Stefan Carlsson, Johan Stranne, Eva Angenete, Olof Akre, Anders Bjartell, Mehbod Mansoori, Carolina Ehrencrona, Peter Wiklund, Eva Haglind","doi":"10.1016/j.euo.2025.05.004","DOIUrl":"https://doi.org/10.1016/j.euo.2025.05.004","url":null,"abstract":"<p><strong>Background and objective: </strong>Localized prostate cancer can be treated with either robot-assisted laparoscopic prostatectomy (RALP) or open retropubic radical prostatectomy (RRP). This study aimed to analyze all-cause and prostate cancer-specific mortality 12 yr after surgery.</p><p><strong>Methods: </strong>The nonrandomized multicenter LAParoscopic Prostatectomy Robot Open (LAPPRO) trial enrolled patients from 2008 to 2011. The eligibility criteria included age <75 yr, prostate-specific antigen <20 ng/ml, clinical stage <T4, nonmetastatic disease, and informed consent. Data were collected through validated questionnaires at baseline and clinical record forms repeatedly up to 12 yr after surgery, with mortality information retrieved from Sweden's National Cause of Death Register. The main outcomes were all-cause and prostate cancer-specific mortality.</p><p><strong>Key findings and limitations: </strong>Of the 4003 patients enrolled in LAPPRO, 3583 were eligible for the current analysis, of whom 2698 (75%) underwent RALP and 885 (25%) RRP. At 12 yr after surgery, prostate cancer-specific mortality was significantly lower after RALP than after RRP (55/2698 [2.0%] vs 40/885 [4.5%]; adjusted hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.23-0.55). The numbers of all-cause deaths were 371/2698 (14%) in the RALP group and 145/885 (16%) in the RRP group (adjusted HR 0.81, 95% CI 0.66-0.99). The study is limited by its nonrandomized design.</p><p><strong>Conclusions and clinical implications: </strong>At 12 yr after surgery, prostate cancer-specific mortality was significantly lower in patients undergoing robotic prostatectomy than in those undergoing open prostatectomy. Cautious interpretation is suggested for the possible causal effect, but the results suggest that the robotic technique is associated with a better oncological outcome.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Isabel Heidegger and Jasmin Bektic's Letter to the Editor re: Michael Baboudjian, Riccardo Leni, Marco Oderda, et al., Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2025.01.009.","authors":"Michael Baboudjian, Guillaume Ploussard","doi":"10.1016/j.euo.2025.05.005","DOIUrl":"https://doi.org/10.1016/j.euo.2025.05.005","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Matthew J. Roberts, Philip Cornford, Derya Tilki. Oncological Benefits of Extended Pelvic Lymph Node Dissection: More Fog or Clarity to the Debate? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.12.001.","authors":"Maria Chiara Sighinolfi, Bernardo Rocco","doi":"10.1016/j.euo.2025.01.014","DOIUrl":"https://doi.org/10.1016/j.euo.2025.01.014","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}